These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33037566)

  • 21. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.
    Balderrama F; Schwartz LJ; Longo CJ
    Health Care Anal; 2020 Jun; 28(2):121-136. PubMed ID: 32232611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.
    Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K
    Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?
    Gerber A; Stock S; Dintsios CM
    Pharmacoeconomics; 2011 Jul; 29(7):549-53. PubMed ID: 21671685
    [No Abstract]   [Full Text] [Related]  

  • 29. German Pharmaceutical Pricing: Lessons for the United States.
    Rodwin MA; Gerke S
    Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 31. Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist.
    Moen E; Toverud EL; Grund J; Brinchmann S
    Pharm World Sci; 1998 Jun; 20(3):107-12. PubMed ID: 9618733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.
    Navarria A; Drago V; Gozzo L; Longo L; Mansueto S; Pignataro G; Drago F
    Value Health; 2015 Jan; 18(1):131-6. PubMed ID: 25595244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Risk-sharing scheme in Israel--Kuvan as an allegory].
    Abadi-Korek I; Shemer J
    Harefuah; 2012 Jun; 151(6):362-3, 377, 376. PubMed ID: 22991868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations.
    O'Donnell H; McCullagh L; Barry M; Walsh C
    Med Decis Making; 2020 Feb; 40(2):144-155. PubMed ID: 32009545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
    Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk sharing in managed entry agreements-A review of the Swedish experience.
    Andersson E; Svensson J; Persson U; Lindgren P
    Health Policy; 2020 Apr; 124(4):404-410. PubMed ID: 32093981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
    Grimm SE; Strong M; Brennan A; Wailoo AJ
    Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managed entry agreements for pharmaceuticals in Australia.
    Vitry A; Roughead E
    Health Policy; 2014 Sep; 117(3):345-52. PubMed ID: 24957419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.